Cargando…
A novel Chk1-binding peptide that enhances genotoxic sensitivity through the cellular redistribution of nuclear Chk1
Since checkpoint kinase 1 (Chk1) is an essential factor for cell viability following DNA damage, the inhibition of Chk1 has been a major focus of pharmaceutical development to enhance the sensitivity of tumor cells to chemo- and radiotherapy that damage DNA. However, due to the off-target effects of...
Autores principales: | Kim, Kwang Seok, Choi, Kyu Jin, Bae, Sangwoo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065296/ https://www.ncbi.nlm.nih.gov/pubmed/28025997 http://dx.doi.org/10.3892/ijmm.2016.2762 |
Ejemplares similares
-
Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001) -
Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity
por: Massey, Andrew J.
Publicado: (2016) -
Regulation of Chk1
por: Tapia-Alveal, Claudia, et al.
Publicado: (2009) -
Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
por: Black, Elizabeth M., et al.
Publicado: (2022) -
Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition
por: Sundararajan, Vignesh, et al.
Publicado: (2022)